immuno-oncology

How an AstraZeneca exec is leading the charge in the next immuno-oncology era
How an AstraZeneca exec is leading the charge in the next immuno-oncology era
Pharma Voice
AstraZeneca
immuno-oncology
Flag link:
Sutro strengthens its immuno-oncology pipeline with two new ADCs
Sutro strengthens its immuno-oncology pipeline with two new ADCs
Clinical Trials Arena
Sutro BioPharma
immuno-oncology
antibody-drug conjugate
Flag link:
Takeda adds another F-Star collab to constellation, this time for $1B in biobucks
Takeda adds another F-Star collab to constellation, this time for $1B in biobucks
Fierce Biotech
Takeda
F-star Therapeutics
bispecific antibodies
immuno-oncology
Flag link:
2 small biotechs morph to work on oncology together
2 small biotechs morph to work on oncology together
Fierce Biotech
CohBar
Morphogenesis
TuHURA Biosciences
immuno-oncology
Flag link:
Innovation in immuno-oncology: Leading companies in microbiota restoration therapy
Innovation in immuno-oncology: Leading companies in microbiota restoration therapy
Clinical Trials Arena
immuno-oncology
microbiome
Flag link:
Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer
Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer
Yahoo/Businesswire
Agenus
immuno-oncology
fast track
FDA
botensilimab
balstilimab
Flag link:
Zymeworks, Daiichi end $293M bispecific collab after 6 unfruitful years
Zymeworks, Daiichi end $293M bispecific collab after 6 unfruitful years
Fierce Biotech
Zymeworks
Daiichi Sankyo
immuno-oncology
biobucks
Flag link:
BeiGene pulls out of Leap of faith, letting option on immuno-oncology candidate lapse
BeiGene pulls out of Leap of faith, letting option on immuno-oncology candidate lapse
Fierce Biotech
BeiGene
immuno-oncology
Leap Therapeutics
DKN-01
Flag link:
Immuno-oncology goes subcutaneous
Immuno-oncology goes subcutaneous
EP Vantage
immuno-oncology
oncology
subcutaneous drug delivery
Keytruda
Merck
Tecentriq
Roche
Flag link:
10 months after first mega round, Glick's Odyssey raises $168M to gear up for entering clinic
10 months after first mega round, Glick's Odyssey raises $168M to gear up for entering clinic
Fierce Biotech
Odyssey Therapeutics
venture capital
immunology
immuno-oncology
Flag link:
Moderna says yes to Autolus, licensing targeting technology for immuno-oncology project
Moderna says yes to Autolus, licensing targeting technology for immuno-oncology project
Fierce Biotech
Moderna Therapeutics
Autolus Therapeutics
MRNA
immuno-oncology
Flag link:
Personalized cancer therapy biotech PACT Pharma lets go of nearly 100 staffers
Personalized cancer therapy biotech PACT Pharma lets go of nearly 100 staffers
Fierce Biotech
Pact Pharma
layoffs
immuno-oncology
Flag link:
Genentech rides up to 2nd target in Bicycle immuno-oncology collab
Genentech rides up to 2nd target in Bicycle immuno-oncology collab
Fierce Biotech
Genentech
Bicycle Therapeutics
Roche
immuno-oncology
Flag link:
Portage Adds Four Adenosine Candidates to Pipeline in Tarus Buyout
Portage Adds Four Adenosine Candidates to Pipeline in Tarus Buyout
BioSpace
Portage
immuno-oncology
Tarus Therapeutics
M&A
adenosine
Flag link:
Astellas pumps $90m into Sutro immuno-oncology alliance
Astellas pumps $90m into Sutro immuno-oncology alliance
Pharmaforum
Astellas
Sutro BioPharma
antibody-drug conjugate
cancer
immuno-oncology
Flag link:
Pfizer-Backed DEM Bio Launches to Leverage CRISPR in Immuno-Oncology
Pfizer-Backed DEM Bio Launches to Leverage CRISPR in Immuno-Oncology
BioSpace
DEM BioPharma
CRISPR
immuno-oncology
Pfizer
Flag link:
Exelixis taps into cancer antibody discoverer out of Sweden
Exelixis taps into cancer antibody discoverer out of Sweden
Endpoints
Exelixis
Bioinvent
cancer
Sweden
immuno-oncology
Flag link:
GO! Astellas picks up partner in convertibleCAR for backloaded $780M antibody project
GO! Astellas picks up partner in convertibleCAR for backloaded $780M antibody project
Fierce Biotech
Astellas
immuno-oncology
R&D
Go Therapeutics
glycoprotein targets
Flag link:
Merck snaps up cancer drug from China’s Kelun in $1.4bn deal
Merck snaps up cancer drug from China’s Kelun in $1.4bn deal
Pharmaforum
Merck
immuno-oncology
China
Sichuan Kelun Pharmaceutical
Flag link:
Silverback falls on hard times, axing lead I/O candidates and laying off more than a fourth of staff
Silverback falls on hard times, axing lead I/O candidates and laying off more than a fourth of staff
Endpoints
Silverback Theraepeutics
cancer
immuno-oncology
layoffs
Flag link:

Pages